Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : Safar Partners
Deal Size : $23.0 million
Deal Type : Series A Financing
Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline
Details : The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.
Brand Name : ENS-002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 02, 2022
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : Safar Partners
Deal Size : $23.0 million
Deal Type : Series A Financing
Lead Product(s) : Alpaca‑derived Nanosized Antibody
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : Max Planck Institute for Multidisciplinary Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to generate and develop NanoAbs with the potential to answering needs underserved by currently approved conventional monoclonal antibody therapeutics as the NanoAbs exhibit potential for patient convenience, safety, and clinical ou...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : Alpaca‑derived Nanosized Antibody
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : Max Planck Institute for Multidisciplinary Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : Leo Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma
Details : LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : Leo Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Enzyme Therapy
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : Kizoo Technology Capital
Deal Size : $8.4 million
Deal Type : Financing
Details : The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fib...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 17, 2022
Lead Product(s) : Enzyme Therapy
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : Kizoo Technology Capital
Deal Size : $8.4 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : Andera Partners
Deal Size : $83.0 million
Deal Type : Series A Financing
Details : The financing will allow to advance four programs of Evommune in pipeline among which three of the compounds include IRAK4/TrkA, broadly inhibits innate inflammation; RORγt, treating inflammation; MRGPRX2, to treat chronic pruritus and fourth compound i...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : Andera Partners
Deal Size : $83.0 million
Deal Type : Series A Financing
Lead Product(s) : EB005
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : GSK
Deal Size : $224.0 million
Deal Type : Collaboration
Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million
Details : Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in a...
Brand Name : EB005
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 11, 2021
Lead Product(s) : EB005
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : GSK
Deal Size : $224.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : University of Dundee
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conv...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 08, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : University of Dundee
Deal Size : Undisclosed
Deal Type : Collaboration